1. The Problem: Eroom’s Law and the Monolith Trap The Economics Are Getting Worse, Not Better Drug development has gotten […]

1. The Effective Patent Life Problem: Numbers, Not Theory Here is what the 20-year patent term looks like from inside

Key Takeaways (Executive Summary) Part I: What Drug Repurposing Actually Is — and Why the Economics Changed Defining the Strategy:

Executive Summary The global CDMO market hit USD 238.92 billion in 2024 and is on track to reach USD 465.24

The Inevitable Horizon: Understanding Loss of Exclusivity (LOE) The pharmaceutical landscape is characterized by cycles of innovation, market exclusivity, and

1. The Stakes: What a Failed 351(k) Filing Actually Costs A Complete Response Letter (CRL) is not an administrative inconvenience.

1. Why Traditional Drug R&D Is Structurally Broken Between 2000 and 2015, more than 86% of drug candidates that entered

An authorized generic is a brand-name drug sold under a generic label. No new FDA approval required. No new manufacturing

The gap between how small-molecule and biologic patents perform at the Patent Trial and Appeal Board has never been wider,